Aravive, Inc.

NasdaqGS:ARAV Stock Report

Market Cap: US$2.9m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Aravive Balance Sheet Health

Financial Health criteria checks 3/6

Aravive has a total shareholder equity of $1.7M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $13.0M and $11.3M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$8.54m
EquityUS$1.70m
Total liabilitiesUS$11.35m
Total assetsUS$13.05m

Recent financial health updates

Analysis Article Apr 26

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article Sep 03

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Recent updates

Analysis Article Apr 26

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article Sep 03

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha Aug 11

Aravive Q2 GAAP EPS misses, revenue beats

Aravive press release (NASDAQ:ARAV): Q2 GAAP EPS of -$0.61 (vs. -$0.35 Y/Y)  misses by $0.02. Revenue of $1.6M (-57.8% Y/Y) beats by $0.67M.
Seeking Alpha Jul 05

Aravive appoints Robert Geller as CMO

Aravive (NASDAQ:ARAV) has announced the appointment of Dr. Robert B. Geller as Chief Medical Officer. Dr. Geller will play a critical role in progressing Aravive’s portfolio of programs in ovarian, renal and pancreatic cancers.
Analysis Article May 15

We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article Nov 06

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article Jun 25

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article Mar 18

Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right stock...
Analysis Article Feb 09

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Financial Position Analysis

Short Term Liabilities: ARAV's short term assets ($9.6M) do not cover its short term liabilities ($9.8M).

Long Term Liabilities: ARAV's short term assets ($9.6M) exceed its long term liabilities ($1.6M).


Debt to Equity History and Analysis

Debt Level: ARAV is debt free.

Reducing Debt: ARAV has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ARAV has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ARAV has less than a year of cash runway if free cash flow continues to grow at historical rates of 8% each year.


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/01/29 15:09
End of Day Share Price 2024/01/29 00:00
Earnings2023/09/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aravive, Inc. is covered by 15 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBTIG
John NewmanCanaccord Genuity
Louise ChenCantor Fitzgerald & Co.